Envestnet Asset Management Inc. Buys 41,487 Shares of Artivion, Inc. $AORT

Envestnet Asset Management Inc. lifted its position in Artivion, Inc. (NYSE:AORT) by 364.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 52,871 shares of the company’s stock after acquiring an additional 41,487 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Artivion were worth $1,644,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in AORT. Next Century Growth Investors LLC increased its stake in Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock valued at $25,140,000 after buying an additional 530,122 shares during the last quarter. Thornburg Investment Management Inc. bought a new stake in Artivion during the first quarter worth $3,261,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Artivion during the first quarter worth $3,162,000. Fred Alger Management LLC purchased a new position in Artivion in the first quarter worth $2,969,000. Finally, Parkman Healthcare Partners LLC bought a new position in Artivion in the 1st quarter valued at $2,744,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Insider Activity at Artivion

In related news, SVP Marshall S. Stanton sold 18,200 shares of the firm’s stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $44.02, for a total value of $801,164.00. Following the sale, the senior vice president directly owned 64,200 shares of the company’s stock, valued at $2,826,084. This trade represents a 22.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jean F. Holloway sold 10,000 shares of Artivion stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $44.37, for a total transaction of $443,700.00. Following the sale, the senior vice president owned 172,129 shares of the company’s stock, valued at approximately $7,637,363.73. The trade was a 5.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 157,251 shares of company stock valued at $7,105,389 in the last ninety days. 8.10% of the stock is currently owned by company insiders.

Artivion Trading Down 0.4%

Artivion stock opened at $44.67 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.04. The stock has a market cap of $2.12 billion, a P/E ratio of -106.35 and a beta of 1.65. The firm’s fifty day moving average price is $42.85 and its 200-day moving average price is $36.72.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. The business had revenue of $113.39 million during the quarter, compared to analysts’ expectations of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm’s revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AORT. Citizens Jmp lifted their target price on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Wall Street Zen raised shares of Artivion from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Citigroup reiterated an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Needham & Company LLC raised their price target on shares of Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Canaccord Genuity Group upped their price objective on Artivion from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and a consensus price target of $49.11.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.